You are viewing: South Korea Humanized Mouse and Rat Model Market analysis

The South Korea Humanized Mouse and Rat Model Market was valued at $2.8 Million in 2025 and projected to reach to $4.1 Million by 2030, representing a compound annual growth rate of 8.1%. South Korea's humanized mouse and rat model market is poised for sustained expansion, driven by the nation's robust biotechnology sector and increasing R&D investments from pharmaceutical companies.

South Korea Humanized Mouse and Rat Model Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

South Korea Humanized Mouse and Rat Model Market Trends and Insights

  • This expansion reflects South Korea's strengthening position in preclinical research and drug development infrastructure.
  • South Korea's investment in biotechnology and pharmaceutical innovation is driving demand for advanced animal models that better replicate human disease pathways. The market in South Korea is supported by the country's robust life sciences ecosystem, including leading research institutions and biopharmaceutical companies.
  • South Korea's regulatory environment and government support for R&D initiatives are accelerating adoption of humanized models in disease research and therapeutic development.
  • Between 2025 and 2030, South Korea is expected to see increased utilization of these models across oncology, immunology, and infectious disease research programs..

Key Market Statistics

  • CAGR (2025-2030) 8.1% CAGR
  • Market Size, 2025 ~USD 2.8 Million
  • Forecast, 2030 ~USD 4.1 Million
  • Country South Korea

South Korea Humanized Mouse and Rat Model Market Overview

Market Valuation :

South Korea's humanized mouse and rat model market is valued at $2.8 million in 2025, with strong growth trajectory positioning it as a key player in Asia-Pacific preclinical research.

Growth Momentum :

The market is expanding at a CAGR of 8.1% through 2030, outpacing many regional markets and reflecting South Korea's commitment to advancing biomedical research capabilities.

Biotechnology Investment :

South Korea's government and private sector investments in biotechnology and pharmaceutical innovation are directly fueling demand for sophisticated humanized animal models in drug development pipelines.

Research Infrastructure :

Enhanced preclinical research facilities and regulatory support in South Korea are attracting both domestic and international pharmaceutical companies seeking advanced in vivo testing solutions.

South Korea Humanized Mouse and Rat Model Market Dynamics

  • The market's projected growth from $2.8 million to $4.1 million by 2030 reflects South Korea's strategic positioning as a regional hub for drug discovery and development.
  • Government initiatives supporting life sciences innovation and the presence of leading biotech firms are accelerating adoption of humanized models for preclinical testing. The market outlook remains positive as South Korean pharmaceutical companies expand their pipelines and international firms establish research collaborations within the country.
  • Increasing regulatory emphasis on reducing animal testing through more predictive models, combined with South Korea's technological capabilities, will continue to drive market penetration.
  • Investment in specialized research facilities and skilled personnel will further strengthen South Korea's competitive advantage in the humanized animal model sector..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • South Korea's humanized mouse and rat model market is valued at $2.8 million in 2025 with a projected CAGR of 8.1% through 2030.
    • South Korea's strong biotechnology sector and government R&D funding are primary drivers of market expansion.
    • South Korea is experiencing increased adoption of humanized models in oncology, immunology, and infectious disease research.
    • South Korea's market is expected to reach $4.1 million by 2030, reflecting growing demand for advanced preclinical research tools.

    Humanized Mouse and Rat Model Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS (CROS AND CDMOS) (End User)
    Forecast Period 2025–2030
    Growth Rate CAGR of 8.2% from 2025 to 2030
    Largest Segment HUMANIZED MOUSE MODELS (Type)
    Market Size Base Year (Billions) ~USD 0.28 (2025)
    Revenue Forecast (Billions) ~USD 0.41 (2030)
    Segments Covered Type, End User, Application

    South Korea Humanized Mouse and Rat Model Market Report Segmentation

    3 segment dimensions are covered across the global market.

    By Type

    • Blt Humanized Mouse Models
    • Cd34 Humanized Mouse Models
    • Cell-Based Humanized Mouse Models
    • Genetic Humanized Mouse Models
    • Humanized Mouse Models
    • Humanized Rat Models
    • Pbmc Humanized Mouse Models

    By End User

    • Academic & Research Institutes
    • Academic And Research Institutes
    • Contract Research Organizations And Contract Development And Manufacturing Organizations (Cros And Cdmos)
    • Cros & Cdmos
    • Cros And Cdmos
    • Pharmaceutical & Biotechnology Companies
    • Pharmaceutical And Biotechnology Companies

    By Application

    • Hematopoiesis
    • Immunology And Infectious Diseases
    • Neuroscience
    • Oncology
    • Other Applications
    • Toxicology

    Target Audience

    • Pharmaceutical Companies : South Korean and international pharma firms need market data to assess preclinical research investment opportunities, identify local suppliers, and plan drug development timelines aligned with regional capabilities.
    • Biotech Research Firms : Biotech companies operating in South Korea require detailed market insights to evaluate demand for humanized models, benchmark against competitors, and justify R&D investments in model development.
    • Contract Research Organizations (CROs) : CROs serving South Korean and regional clients need market forecasts to expand service offerings, allocate resources to preclinical testing divisions, and identify growth segments within animal model services.
    • Government & Policy Makers : South Korean government agencies and research councils use market data to inform biotech policy, allocate research funding, and assess the nation's competitive position in global preclinical research infrastructure.
    • Academic Research Institutions : Universities and research centers in South Korea need market intelligence to secure funding, establish industry partnerships, and align their humanized model research programs with commercial demand trends.

    Key Companies in the South Korea Humanized Mouse and Rat Model Market

    CompanyHQOwnershipStrongest segments
    CHARLES RIVER LABORATORIESUnited StatesPublic CompanyResearch Models and Services,Discovery and Safety Assessment,Manufacturing Solutions,
    THE JACKSON LABORATORYUnited StatesFoundation/Charitable InstitutionMouse breeding and colony management,Phenotyping, efficacy testing, and genetic research services,Genetic resources, software, and data,
    INOTIVUnited StatesPublic CompanyResearch Models and Services (RMS),Discovery and Safety Assessment (DSA) Services,BASi Scientific Instruments and Software,
    GENOWAYFrancePublic CompanyCustom mouse models (KO/KI and humanized),Custom rat models,Engineered cell lines,
    JSR CORPORATIONJapanPrivate CompanyDigital Solutions (lithography, photoresists, CMP, display and packaging materials),Plastics / Synthetic Resins (ABS, AES, AS, ASA and related resins),Life Sciences (diagnostic and research reagents, bioprocess materials, drug discovery support),
    CHAMPIONS ONCOLOGY, INC.United StatesPublic CompanyTumorgraft / PDX-based translational oncology services,Personalized cancer care services,Lumin Bioinformatics and data-driven software,
    ONCODESIGN SERVICESFrancePublic CompanyPrecision oncology and immuno-oncology (OPM-101, OPM-102),Neurodegeneration (OPM-201, Parkinson’s),Radiotheranostic portfolio for digestive and pancreatic cancers,

    CHARLES RIVER LABORATORIES

    Charles River Laboratories is a public company founded in 1947 in the United States with 19,000 employees.

    THE JACKSON LABORATORY

    The Jackson Laboratory is a foundation-based charitable institution founded in 1929 in the United States with 2,100 employees.

    INOTIV

    Inotiv is a public company founded in 1974 in the United States with 1,996 employees.

    GENOWAY

    Genoway is a public company founded in 1999 in France with 157 employees.

    JSR CORPORATION

    JSR Corporation is a private company founded in 1948 in Japan with 7,997 employees.

    CHAMPIONS ONCOLOGY, INC.

    Champions Oncology, Inc. is a public company founded in 1985 in the United States with 214 employees.

    ONCODESIGN SERVICES

    Oncodesign Services is a public company founded in 1995 in France.

    Reasons to Buy this Report

    • Market-Specific Sizing : Access precise valuation data for South Korea's humanized animal model market with verified 2025 baseline ($2.8M) and 2030 forecasts ($4.1M), enabling accurate budget allocation and investment planning.
    • Regional Growth Intelligence : Understand South Korea's 8.1% CAGR trajectory and competitive positioning within Asia-Pacific, identifying expansion opportunities ahead of market saturation in mature regions.
    • Localized Industry Drivers : Gain insights into South Korea-specific factors including government biotech initiatives, pharmaceutical company R&D strategies, and regulatory environment shaping market demand and growth patterns.
    • Strategic Partnership Opportunities : Identify key South Korean research institutions, biotech firms, and pharmaceutical companies actively investing in humanized models, enabling targeted collaboration and market entry strategies.
    • Competitive Landscape Analysis : Benchmark your organization against South Korean market participants and understand local competitive dynamics, pricing strategies, and differentiation opportunities specific to this emerging market.

    Frequently asked questions

    What is the current market size of humanized mouse and rat models in South Korea?

    South Korea's humanized mouse and rat model market was valued at $2.8 million in 2025.

    What is the projected market size for South Korea by 2030?

    South Korea's market is projected to reach $4.1 million by 2030, representing a compound annual growth rate of 8.1%.

    What factors are driving growth in South Korea's humanized model market?

    South Korea's growth is driven by increased biotechnology investment, government R&D support, and rising demand for advanced preclinical research tools in drug development.

    Which therapeutic areas are driving demand in South Korea?

    South Korea is seeing increased adoption of humanized models in oncology, immunology, and infectious disease research programs.

    How does South Korea's market compare to global trends?

    South Korea's CAGR of 8.1% is closely aligned with the global market CAGR of 8.2%, indicating consistent regional performance within broader market trends.

    RESEARCH METHODOLOGY

    The research study used secondary sources, directories, and databases to identify and collect valuable information to analyze the global humanized mouse and rat model market. Widespread interviews were conducted with various primary participants, including key industry members, subject-matter experts (SMEs), C-level managers of leading market players, and industry consultants, to obtain and verify qualitative and quantitative information and evaluate the growth scenarios of the market. The global market size was estimated through secondary research (top-down and bottom-up), followed by data triangulation with inputs from industry experts to determine the final market size.

    Secondary Research

    Secondary research was used to identify and collect information for the technical, market-oriented, and commercial study of the humanized mouse and rat model market. The secondary sources used for this study include the American Association for Cancer Research (AACR), American Association for Laboratory Animal Science (AALAS), European Society for Medical Oncology (ESMO), European Association for Cancer Research (EACR), Humanized Mouse Resource (HMR), National Center for Biotechnology Information (NCBI), and Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC).

    Academic Journals and Company Websites; corporate & regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations were also used to obtain major information about key market players and market segmentation corresponding to industry trends, regional/country-level markets, market developments, and technology prospects. Secondary data was collected and analyzed to determine the market size of the global humanized mouse and rat model market, which was further validated through primary research.

    Primary Research

    Primary research was conducted after acquiring basic knowledge about the global humanized mouse and rat model market through secondary research. A series of primary interviews were conducted with market experts from the demand side, including professionals from the pharmaceutical and biopharmaceutical industries and academic institutions. Additionally, interviews were held with individuals from the supply side, such as C-level and D-level executives, product managers, and marketing and sales managers from key manufacturers, distributors, and channel partners. The primary interviews were conducted across North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 80% and 20% of the primary interviews were conducted with supply-side and demand-side participants. This data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

    The breakdown of the primary respondents is given below.

    Humanized Mouse and Rat Model Market

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    Top-down and bottom-up approaches were used to estimate and validate the total size of the humanized mouse and rat model market. These methods were also used extensively to estimate the size of various subsegments in the market.

    Humanized Mouse and Rat Model Market

    Data Triangulation

    After determining the market size from the above estimation process, the total market was divided into several segments and subsegments. Where applicable, data triangulation and market breakdown procedures were employed to complete the overall market engineering process and determine the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from the demand and supply sides.

    Market Definition

    A humanized mouse and rat model is an immunodeficient organism genetically engineered to study immune responses to drugs or identify potential disease targets. These models are widely used to study human diseases and genes. Researchers in both academia and industry, along with clinicians, extensively use humanized mouse and rat models in their research applications. Humanized mouse and rat models are beneficial tools for immuno-oncology and infectious disease research. They have improved the ability to predict human responses to new therapeutics in clinical development.

    Stakeholders

    • Research and consulting firms
    • Biopharmaceutical manufacturers
    • Pharmaceutical manufacturers
    • Mouse model and service companies
    • Government and private research institutes
    • Manufacturers and suppliers of animal care products
    • Clinical research organizations (CROs)
    • Academic and research institutes
    • Venture capitalists
    • Laboratory animal care associations
    • Public and private animal health agencies

    Report Objectives

     

    To define, describe, and forecast the humanized mouse and rat model market by type, application, end user, and region

    To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)

    • To analyze the micromarkets1 concerning individual growth trends, prospects, and contributions to the overall humanized mouse and rat model market
    • To assess the opportunities for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments for North America, Europe, the Asia Pacific, Latin America, Middle East, and Africa
    • To profile the key players and analyze their market shares and core competencies2
    • To track and analyze competitive developments, such as product/service launches, partnerships, agreements, collaborations, and expansions
    • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

     

    Get the Full Humanized Mouse and Rat Model Market Report

    Full forecast, segment splits, and company analysis for all Humanized Mouse and Rat Model Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status